Using AI to help diagnose skin conditions in primary care
Official title: Application of the Belle.AI Dermatological Image Reference System on Patient Diagnosis Within an Active Clinical Setting
Run by BelleTorus Corporation · NCT06724627 · Data updated 2026-11-12
This study is testing an AI app that helps primary care doctors diagnose skin conditions more accurately by comparing their findings to a panel of dermatologists.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 263 (estimated) |
| Sponsor | BelleTorus Corporation Industry-sponsored |
| Locations | 1 site (The Bronx, New York) |
| Status | Recruiting |
| Started | September 16, 2024 |
| Main results expected | March 30, 2025 |
| Study ends | June 30, 2025 |
| Registry record updated | December 9, 2024 |
| Trial ID | NCT06724627 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients presenting with primary dermatological complaints at walk-in clinics who can provide informed consent and use the required technology.
✕Probably not a fit
Patients with physical or mental health limitations that prevent compliance with study procedures, as well as pediatric patients with genital dermatological conditions, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research evaluates an AI-powered dermatology image reference app designed to assist primary care providers in diagnosing skin conditions. The app provides reference images based on a convolutional neural network trained on over 500,000 images, allowing providers to compare their assessments with a panel of dermatologists. The study aims to determine the effectiveness of this tool in enhancing diagnostic accuracy for non-specialists in real-time clinical settings. By comparing diagnoses made with and without the AI tool, the research seeks to understand its potential role in improving patient care.
Why it matters
Potential benefit: If successful, this tool could significantly enhance the diagnostic accuracy of primary care providers, leading to better patient outcomes for skin conditions.
How similar studies have gone: Previous studies have shown that AI tools can enhance diagnostic accuracy for dermatological conditions, particularly for non-specialists, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient must present to walk-in clinic with a primary dermatological complaint. * Patient must have the ability and willingness to provide informed consent and comply with study procedures and visits. * Participants must have access to the required technology (e.g., smartphone with internet access) and be capable of using it for the required image capture. Exclusion Criteria: * Patients who are unable to comply with study procedures due to physical or mental health limitations (as assessed by study coordinator). * Pediatric, adolescent, and teen patients who present with dermatological conditions on their genitalia will not be included in the study (in support of patient privacy concerns).
Where it's running
-
Urban Health Plan Inc.
The Bronx, New York, United States Recruiting
Study contacts
- Principal investigator: John Romano, MD — BelleTorus Corporation
- Study coordinator: John Romano, MD
- Email: jromano@belle.ai
- Phone: 617-520-4730
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid vitamin C and glutathione sachets for skin health
This test tries whether daily liquid vitamin C plus glutathione sachets improve skin appearance and reduce oxidative stress in healthy adults aged 18–65.
-
Evaluating a food supplement for improving skin and hair conditions
This study is testing whether a food supplement can improve skin and hair conditions in people over two months compared to a placebo.
-
Cutaneous and Mucosal Signs in Children with Neurofibromatosis Type 2
This study looks for skin and mucous membrane signs in kids under 15 who have neurofibromatosis type 2 to see if these features can help with early detection when other symptoms are present.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.